BeyondSpring announces Dublin-3 final phase 3 efficacy data of its late clinical-stage agent Plinabulin in combination with docetaxel in second/third line advanced and metastatic non-small cell lung cancer, NSCLC, with epidermal growth factor receptor, EGFR, wild-type. The lead principal investigator, Dr. Trevor Feinstein from Piedmont Cancer Institute, presented the data in an oral presentation at ISLAC 2024 World Conference on Lung Cancer on September 9th 2024 in San Diego, CA. Statistically Significant and Clinically Meaningful Efficacy Data with Favorable Benefit/Risk ratio from DUBLIN-3 Phase 3 Study of Plinabulin plus Docetaxel vs. Docetaxel in EGFR Wild-Type NSCLC after Progression on Platinum-based Therapy
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BYSI:
- BeyondSpring Announces Oral Presentation at the 2024 World Conference on Lung Cancer and Two Poster Presentations During ESMO Congress 2024 Showcasing its Lead Anti-Cancer Asset, Plinabulin
- BeyondSpring Inc. Reports Mid-Year Financials
- SEED and Eisai Partner on Groundbreaking Biotech Research
- SEED Therapeutics enters strategic research collab with Eisai
- SEED Therapeutics (SEED) Enters into Strategic Research Collaboration with Eisai Co., Ltd. to Discover and Develop Novel Molecular Glue Degraders for Neurodegeneration and Oncology Indications